J Clin Oncol 31, 2013 (suppl; abstr 8543)
Andrzej J. Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Jagoda Jasielec, Kathryn McDonnell, Daniel Lebovic, David H Vesole, Sundar Jagannath, Elaine G. Chottiner, Tara B. Anderson, Kristen Detweiler-Short, Keith Stockerl-Goldstein, Asra Z. Ahmed, Terri L. Jobkar, Diane E. Durecki, Melissa A Mietzel, Daniel R. Couriel, Ravi Vij, Mark Stefan Kaminski; University of Chicago Medical Center, Chicago, IL; Poznan University of Medical Sciences, Poznan, Poland; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; University of Chicago, Winooski, VT; The University of Chicago Medicine and Biological Sciences, Chicago, IL; University of Michigan, Ann Arbor, MI; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Mount Sinai Medical Center, New York, NY; University of Michigan Medical Center, Ann Arbor, MI; Washington University School of Medicine in St. Louis, St. Louis, MO; University of Michigan Hospital, Ann Arbor, MI; Washington University in St. Louis, St Louis, MO
Background: We previously reported results from a phase 1/2 trial of CRd in NDMM (NCT01029054), demonstrating a high rate (42%) of stringent complete response (sCR) and overall favorable efficacy /safety after a median of 12 cycles of treatment (tx) and a median follow-up of 13 mo (Jakubowiak et al Blood, 2012). Here we report updated results after extended tx and additional 12 mo of follow-up.
Methods: Patients (pts) received 28-day (d) cycles of carfilzomib (CFZ) 20–36 mg/m2 IV (d1, 2, 8, 9, 15, 16), lenalidomide (LEN) 25 mg PO (d1–21), and dexamethasone 40/20 mg PO wkly (cycles 1–4/5–8). For cycles 8–24, CRd was given with a modified CFZ schedule (d1, 2, 15, 16) and then LEN alone after cycle 24. Stem cell transplant was an option after cycle 4. Response was assessed by IMWG plus nCR.
Results: As of Nov 2012, 53 pts had received a median of 22 CRd cycles (range 2–24); 7 pts opted for transplant; 24 continued LEN maintenance for median 8 mo (range 1–10). Median follow-up was 25 mo (range 5–37). With extended tx, the CR rate was 64%; sCR improved from 42% to 53%, ≥nCR from 62% to 72%, and ≥VGPR from 81% to 87% (follow-up 13 vs 25 mo); ≥PR remained at 98%. Immunophenotypic CR (IMWG) was achieved in 22/26 evaluated pts. Of pts in sCR, 25% had high-risk cytogenetics per IMWG. In pts who did not proceed to transplant (n=46), the sCR was 59%, CR 70%, ≥nCR 78%, ≥VGPR 91%, and ≥PR 100%. Over the course of tx, depth of response improved. Median time to ≥VGPR was 4 cycles (range 2–17), ≥nCR 4.5 cycles (range 2–15), and sCR 10 cycles (range 4–30); 2 pts converted to sCR during LEN maintenance. At 2 years, the estimated PFS rate was 94% and OS was 98%; for pts with sCR, rates were 96% and 100%, respectively. Adverse event types, rates, and dose modifications during extended tx were comparable with those previously reported. There was 1 death off study due to disease progression.
Conclusions: Extended follow-up showed that depth of response continued to improve over the course of prolonged CRd tx, resulting in exceptional CR, sCR, and PFS. Extended tx continued to be well tolerated. The results compare favorably with historical studies in both transplant and non-transplant NDMM.
Clinical trial information: NCT01029054.